Elliott, Brian
Genmab (United States)
4 papers on CoChatORCID 0000-0003-4163-0159
Most cited papers
- Verified
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
Thieblemont, C., Phillips, T., Ghesquieres, H., Cheah, C. Y., Clausen, M. R., Cunningham, D., Do, Y. R., Feldman, T., Gasiorowski, R., Jurczak, W., et al. (2023) · Journal of Clinical Oncology
Lymphoma Diagnosis and TreatmentCAR-T cell therapy research
Cited by 584
- Verified
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Hutchings, M., Mous, R., Clausen, M. R., Johnson, P., Linton, K. M., Chamuleau, M. E. D., Lewis, D. J., Sureda Balari, A., Cunningham, D., Oliveri, R. S., et al. (2021) · The Lancet
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 337
- Verified
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
Linton, K. M., Vitolo, U., Jurczak, W., Lugtenburg, P. J., Gyan, E., Sureda, A., Christensen, J. H., Hess, B., Tilly, H., Cordoba, R., et al. (2024) · The Lancet Haematology
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 171
- Verified
Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas
Li, T., Hiemstra, I. H., Chiu, C., Oliveri, R. S., Elliott, B., DeMarco, D., Salcedo, T., Egerod, F. L., Sasser, K., Ahmadi, T., et al. (2022) · Clinical Pharmacology & Therapeutics
Monoclonal and Polyclonal Antibodies ResearchLymphoma Diagnosis and Treatment
Cited by 34
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free